Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. - Wikidata - awgldk - TriplyDB

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

http://www.wikidata.org/entity/Q33924515

about

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based review Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis.Reovirus: a targeted therapeutic--progress and potential.Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Oncolytic virotherapy for urological cancers.Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.Current understanding of reovirus oncolysis mechanisms.Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranostics Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis

P2860

Q26750568-5628D797-2E08-49CB-8064-590A79D4F34A Q26775030-C73BD5C4-9958-485A-9C2D-920E19A0D430 Q26775033-3694B3DF-9873-4C9D-97C6-6714D39D968C Q26863779-9A237E2C-CBE1-48D5-9B96-FA87D60A5B39 Q33828697-3A11B404-5B09-4A79-AD86-6731FD027F1A Q34763999-0FFFB4D4-2BA7-4E39-AB92-036879BBB079 Q36390114-229691F3-AC24-465B-B5D0-C6ABC6C6BAAD Q36574519-5B74C400-5B96-483A-AA76-51E7F62930C5 Q36757045-E9F07244-1AE1-4D63-84D6-B73408D27997 Q36766052-20596AD6-BDDC-4EB3-84D5-B2F4AF378A8F Q37031909-CEF5445D-D7A2-4F28-A768-A3FABDC62B52 Q37352017-63909262-AC87-41FF-A37C-920952C730CE Q37360608-2116B170-54C9-48EB-A05B-50F6D97D14E8 Q37565521-A94FFEBB-FD48-4A13-8DE5-21FCE85ECE28 Q38025696-700FAEB9-864C-4DDE-95A4-8B962DF52CB4 Q38058884-D3445AA1-ADAE-497A-9BC8-980D23695867 Q38458133-64EEEBBD-8F3B-4292-AC48-408B62E0BFF8 Q38653084-92CEA6E8-8232-4F21-BC3E-52FB05504CCF Q38842126-DFE2335A-5D69-4F71-8277-EBB9E24D6984 Q38844346-7DAAF500-06EB-4B3C-B6F1-6DF823DD212E Q38916660-A9CD67B5-7D20-4251-9A13-5D5BCBDB14EA Q38998279-9EEF7F6B-0911-4ADC-9DF3-744F7D430CA1 Q39159172-19BD2A3A-DA88-41EA-8D26-FF3DB972CF21 Q39205115-E407D5B3-E19C-459E-A1F5-6DC5F5DAEE20 Q39247147-D4AD1EB9-7623-45FB-B751-6235D66BC015 Q39247534-B8C59AD9-0D6D-4695-BF4D-4AD0B1DD9D65 Q40907752-25E95596-5180-4E6C-B52F-1F96B50DC922 Q40952636-2CFF20A2-0BED-4884-998D-842302B21A9F Q47096886-201ADA4B-5905-4156-B832-1BEF88B5AB24 Q52718361-8E5D55D5-AC85-4D9D-A23B-6A262275BA74 Q55427397-F396D453-9C63-4B7A-A5B4-D28684825AA0 Q57181751-6F5E8BFC-0418-4B1D-9773-A72F7BFD6A3D Q58718145-02898AEE-139F-4304-A1D5-5FE7EF2DAE1D

P2860

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

http://www.wikidata.org/entity/Q33924515

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@ast

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en-gb

type

label

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@ast

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en-gb

prefLabel

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@ast

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en-gb

P1433

Q33924515-AC34BA22-1724-4A18-95CF-0950C87804F6

P1476

Q33924515-10BBBD3A-F2EF-4B16-9DE7-9B96EC618E5C

P2093

Q33924515-3D504C55-6F53-4A9F-BBDD-B773E5272421

Q33924515-49322093-85A3-4942-B959-491B3D5BE075

Q33924515-5E1662A8-18EE-4CEA-A812-063F29DB2FC8

Q33924515-6FFF8904-3237-4120-8281-944FA3244270

Q33924515-7EA45B91-E44B-4DD4-A180-F7763861B263

Q33924515-837DABF1-336D-4672-B516-0FDB1A6FF950

Q33924515-8D1F2108-A409-4833-9723-0927F1B78F9D

Q33924515-A135BCAD-C6AE-47C4-B26E-315C7184324A

Q33924515-D542F06E-3087-4822-872C-9E17CDEBD1D5

Q33924515-EED13369-EA62-4B71-810C-7D6AE931BE0A

P2860

Q33924515-026139DC-4BB3-448E-9EE7-E10E3A15F472

Q33924515-06492575-BD7D-4DB0-8112-A9E3795F3DF3

Q33924515-0B6CD1F7-7FBF-4779-B756-8CC9FD55EE85

Q33924515-0E0EC083-62A5-47EA-83F7-CA3CEAA08473

Q33924515-1425C3A9-E337-4E4D-B7AC-77C00845E948

Q33924515-18327FF2-958B-4DA9-9C47-BA5819CEF833

Q33924515-22B0A50A-252D-4995-B67D-C36D24A32636

Q33924515-280FDDD7-335C-45ED-B7E3-F5D5F58C4391

Q33924515-3913F0B9-947C-417C-88F2-8D84CEE8F108

Q33924515-40A41BCC-3E8D-461E-8EB2-4D6C3EAAEBD0

P2888

Q33924515-14B45D0C-BD3E-43DB-A665-D19F23E34F5F

P304

Q33924515-E1398296-A7A0-4A76-A792-602F26B318C7

P31

Q33924515-5A90EB27-DC09-4833-A6BF-95331B544ACF

P356

Q33924515-013C1050-B0AB-4C99-8BBD-3449601251E1

P407

Q33924515-DFE0E5D2-B1C8-4CE3-8468-ECB23DAB1029

P478

Q33924515-3162C641-C40E-474E-8942-883110EA9C79

P50

Q33924515-EFD42EB0-C377-4921-8F04-F9783FAA6D5F

P577

Q33924515-EA59E239-587A-4E4B-B101-0C5D52A14E8F

P5875

Q33924515-554FB24F-E056-449F-92D2-A30ADB17D7D1

P6179

Q33924515-9644EAFF-BE07-416B-B31C-CFFB49E68DCB

P698

Q33924515-6B75FEB0-8A92-4B75-B0BC-F25FC8B91D67

P921

Q33924515-44253D41-0B02-4BE6-BF47-9C4FC2147E26

Q33924515-481A4560-0656-48F5-8705-F7BC4B8AC7EE

P932

Q33924515-A7C77E88-A650-4B5A-8510-A89B77A19748

P356

1471-2407-11-221

P1433

P1476

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

@en

P2093

Angela Boxall

http://www.w3.org/2001/XMLSchema#string

Guy R Simpson

http://www.w3.org/2001/XMLSchema#string

Hardev S Pandha

http://www.w3.org/2001/XMLSchema#string

Kate L Relph

http://www.w3.org/2001/XMLSchema#string

Kevin J Harrington

http://www.w3.org/2001/XMLSchema#string

Lucy Heinemann

http://www.w3.org/2001/XMLSchema#string

Richard Morgan

http://www.w3.org/2001/XMLSchema#string

Richard Vile

http://www.w3.org/2001/XMLSchema#string

Robin Prestwich

http://www.w3.org/2001/XMLSchema#string

Timothy Kottke

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Differential sensitivity of normal and transformed human cells to reovirus infection

Comparisons of the M1 genome segments and encoded mu2 proteins of different reovirus isolates

Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu2

Targeting RAS signalling pathways in cancer therapy

Microtubules as a target for anticancer drugs

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P2888

1471-2407-11-221

P304

221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-221

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51195534

http://www.w3.org/2001/XMLSchema#string

P6179

1007296371

http://www.w3.org/2001/XMLSchema#string

P698

21645351

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3129324

http://www.w3.org/2001/XMLSchema#string